Anna Schorer, M.D.

VA Medical Center

Selected Publications

Schorer AE, Moldow CF, Rick ME.  Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells.  Br J Haematol 1987; 67;193-197.

Vercellotti GM, Dobson M, Schorer AE, Moldow CF. Endothelial cell heterogeneity: Antioxidant profiles determine vulnerability to oxidant injury.  Proc Soc Exp Biol Med 1988.

Schorer AE, Wickham NW, Watson KV.  Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation.  Br J Haematol 1989; 71:399-407.

Schorer AE, White JG.  Interleukin 1 enhances arterial thrombogenicity in vitro.  Thromb Res 1989; 56:515-522.

Shultz PJ, Schorer AE, Raij L.  Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells.  Am J Physiol 1990; 258:F162-F167.

Watson KV, Schorer AE.  Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients.  Am J Med 1991; 90:47-53.

Schorer AE, Duane PG, Woods VL, Niewoehner DE.  Some antiphospholipid antibodies inhibit phospholipase A2 activity.  J Lab Clin Med 1992; 120:67-77.

Schorer AE, Singh J, Basara ML.  Dysfibrinogenemia: A case with thrombosis (fibrinogen Richfield) and an overview of the clinical and laboratory spectrum.  Am J Hematol 1995; 50:200-208.

Schorer AE.  Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody.  Thromb Res 1997; 85:295-304.